Free Stipulation - District Court of Delaware - Delaware

Case 1 :07-cv-00360-JJF Document 31 Filed 03/19/2008 Page 1 of 2
IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE
PFIZER, INC., ) `
PPIZER IRELAND PHARMACEUTICALS,)
WARNERIAMBERT COMPANY, )
WARNER—LAMBERT COMPANY, LLC ) ·
and ) ‘
WARN ER-LAMBERT EXPORT LTD., )
i )
Plaintiffs, ) Civil Action No. 07-3 60-JJF
_ )
v. )
)
TEVA PHARMACEUTICALS USA, INC., ) ‘
)
5 Defendant. . )
` STIPULATION
Defendant Teva Pharmaceuticals USA, Inc. ("Teva”) and plaintiffs Pfizer, Inc., Pfizer
Ireland Pharmaceuticals, Warner—Lambert Company, Warner—Lambe1t Company, LLC and
Warner-Lambert Export Ltd. (collectively referred to as "Pfizer"), hereby stipulate and agree as
follows: ,
1. i Pfizer and Teva agree that the only claim of U.S. Patent 5,273,995 ("the ’995
patent") that Pfizer will assert in this litigation is claim 2. "
2. Pfizer covenants not to assert infringement under any section of 35 U.S.C. § 271
of claims l, 11 or 12 of the ‘995 patent, or any corresponding claims in any. reissue of the ‘995
patent, with respect to the tablets that are the subject of AN DA No. 78-773 (ANDA TABLETS)
and the atorvastatin calcium salt active pharmaceutical ingredient when used to make the ANDA
TABLETS. For purposes of clarity, this covenant does not extend to claims 6, 13 and 14 in any
reissue patent arising from reissue application l 1/ 653 830, or claim 2 in any. patent reissue arising
from reissue application 11/973897 or any corresponding claims thereof.
3. Teva withdraws its 30(b)(6) deposition notice served on March 7, 2008.
59935l_l.DOC

Case 1 :O7—cv-00360-JJF Document 31 Filed 03/19/2008 Page 2 of 2
4. Fact discovery, which closes on April 1, 2008, shall be extended with respect to
the following matters:
(a) Pfizer shall serve, by April 14, 2008, a second supplemental response to
interrogatory No. 3 of Teva’s First Set of Interrogatories ("Pfizer’s second supplemental
response") in order to provide detailed information relating to the issue of secondary
considerations of non-obviousness of claim 2 of the ’995 patent.
(b) After reviewing Pfizer’s second supplemental response, Teva may, if
necessary, serve a 30(b)(6) deposition notice relating to the issue of secondary considerations of
non-obviousness of claim 2 of the ’995 patent.
Dated: March 19, 2008
/s/ Jejfirey B. Bova /s/ Richard D. Kirk
Rudolf E. Hutz (#484) Richard D. Kirk (#922)
Jeffrey B. Bove (#998) Ashley B. Stitzer (#3891)
Mary W. Bourke (#2356) BAYARD, P.A.
CONNOLLY BOVE LODGE & I-TUTZ LLP 222 Delaware Avenue, Suite 900
The Nemours Building Wilmington, DE 19899-5130
1007 North Orange Street (302) 655-5000
P.O. Box 2207 i
Wilmington, DE 19899-2207 Attorneys for Defendant
(302) 658-9141 TEVA PHARMACEUTICALS USA, INC
Attorneys for Plaintiffs OF COUNSEL:
David M. Haslnnall
_ Frederick H. Rein
Emily L. Rapalino
Joseph B. Crystal
GOODWIN PROCTER LLP
599 Lexington Avenue
New York, NY 10022
(212)813-8800
IT ISISO ORDERED this day of , 2008.
3 United States District Judge
599351_l.DOC